BioLife Sciences Announces Launch of Hemp-Based Product Line
BioLife Sciences Announces Launch of Hemp-Based Product Line
HENDERSON, Nev., Aug. 17, 2022 (GLOBE NEWSWIRE) -- BioLife Sciences Inc. ("BioLife" or the "Company") (OTC: BLFE) announced today the launch of its first line of cannabinoid consumer products. The Company will be offering six distinct industrial hemp-based tincture formulations. The hemp sciences division will be a subsector of the orthomolecular medicine and natural health products line.
亨德森，新加州，2022 年 8 月 17 日（環球新聞社）-生物生命科學公司（「生物生命科學」或「公司」）（OTC：BLFE）今天宣布推出其第一系列大麻素消費產品。該公司將提供六種不同的工業大麻基酊劑配方。大麻科學部門將是正分子醫學和天然健康產品系列的子部門.
BioLife has finalized formulations on six new tinctures. These new formulas were driven by the Company's recent acquisition of Health Box LLC in early 2022.
BioLife 已經完成了六種新酊劑的配方。這些新配方是由該公司最近在 2022 年初收購健康箱有限責任公司的推動。
Each tincture will feature varying mixes of non-psychoactive cannabinoids and robust terpene profiles, designed for maximizing the health benefits for consumers.
每種酊劑都將具有不同的非精神活性大麻素混合物和強大的萜烯輪廓，旨在為消費者帶來最大限度地提高健康益處。
BioLife will not only focus on CBD products, but will offer synergistic blends which utilize the lesser known cannabinoids, including, but not limited to, CBG, CBN, CBGA, CBDA, CBNA, plant terpenes and flavonoids.
BioLife 不僅將專注於 CBD 產品，而且將提供利用鮮為人知的大麻素的協同混合物，包括但不限於 CBG，CBN，CBGA，CBDA，CBNA，植物萜烯和黃酮類化合物。
"The majority of existing hemp products currently available utilize isolates of cannabinoids," said Nika Jaksic, COO of BioLife Sciences. "We find this is the least effective way to tap into the full benefits of the hemp plant and its healing powers. By harnessing hemp's full spectrum of cannabinoids, terpenes, flavonoids and other plant compounds, consumers will be able to access the full benefits of the plant and as such, they will garner the maximum health benefits."
「目前可用的大多數現有大麻產品都使用大麻素的分離物,」Nika Jaksic 說, 生物生命科學首席運營官.「我們發現這是充分利用大麻植物及其治療能力的全部好處的最有效方法.通過利用大麻的全系列大麻素，萜烯，類黃酮和其他植物化合物，消費者將能夠獲得植物的全部好處，因此，它們將獲得最大的健康益處。」
Hemp products that are listed as full spectrum, for producing the entourage effect, a term used to describe the plant's compounds working together to offer more complete relief. This is in direct contrast to products which only utilize CBD isolate, Additionally, full-spectrum products have had all THC traces removed.
被列為全譜的大麻產品, 用於產生隨從效應, 用於描述植物的化合物共同努力提供更完整的救濟的術語.這與僅使用 CBD 分離物的產品形成直接對比，此外，全光譜產品已刪除所有 THC 痕跡。
BioLife intends to continue to expand its hemp-based product line once the tinctures have been released, with plans on expanding to salves, syrups, coffees, teas and lotions.
BioLife 打算在酊劑發布後繼續擴大其大麻產品線，並計劃擴展到藥劑，糖漿，咖啡，茶和乳液。
CBD usage has steadily increased in the U.S. since 2018, with multiple peer-reviewed studies having confirmed that the cannabinoid may help with a wide variety of ailments and conditions, including, but not limited to, pain, stress, weight loss, anxiety and depression.
自 2018 年以來，CBD 的使用率在美國穩步增加，多項同行評審研究證實，大麻素可能對各種疾病和條件有所幫助，包括但不限於，疼痛，壓力，減肥，焦慮和抑鬱。
The Brightfield Group recently announced projections for the hemp CBD industry to continue to expand in 2022, with a projection of nearly 400% growth to $22 billion by the end of the year.
布萊特菲爾德集團最近宣布了對大麻 CBD 行業的預測將繼續擴大 2022, 預計將近 400% 增長到 $22 到今年年底十億.
About BioLife Sciences Inc.
BioLife Sciences Inc. specializes in moving innovative products from the lab or small-scale production into wider market adoption. Its core business develops, licenses and distributes antimicrobial products and disruptive technology. One of BioLife Sciences' core building block strategies is to develop, partner and assist innovative companies with the commercialization of leading-edge technologies.
關於生物生命科學公司
BioLife Scienciences Inc. 專門從實驗室或小規模生產將創新產品轉移到更廣泛的市場採用。其核心業務開發、授權和分銷抗菌產品和顛覆性技術。BioLife Scienciences 的核心構建基礎策略之一是開發，合作和協助創新公司將尖端技術商業化。
Disclaimer:
The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward-looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the ability of the Corporation to complete a qualifying transaction. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward-looking statements are reasonable, it can give no assurance that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.
免責聲明：
本新聞稿中的信息包括有關管理層對未來事件，期望，計劃和前景的觀點的某些信息和聲明，這些信息構成前瞻性陳述。這些聲明是基於承受重大風險和不確定因素的假設。由於這些風險和不明朗因素，以及由於各種因素，實際結果、期望、成就或表現可能與這些前瞻性陳述所預期和表現有重大差異。本新聞稿中的前瞻性聲明包括但不限於公司完成合格交易的能力。任何數量的因素都可能導致實際結果與這些前瞻性陳述以及未來結果有很大不同。雖然港鐵公司相信前瞻性陳述所反映的期望是合理的，但不能保證任何前瞻性陳述的期望都是正確的。除法律規定外，本公司不承擔任何意圖，亦無義務更新或修改任何前瞻性陳述以反映實際結果，無論是由於新資訊、未來事件、假設的變動、影響該等前瞻性陳述的因素的變更或其他原因而造成的。
Contact Information:
ir@biolifesciences.com
US & Canada: 1 (833) 919-1037
聯絡資訊：
ir@biolifesciences.com
美國及加拿大：1 (833)
譯文內容由第三人軟體翻譯。